Ambrisentan Fails in Lung Fibrosis (CME/CE)

(MedPage Today) -- The pulmonary hypertension drug ambrisentan (Letairis) was supposed to tackle one of the root causes of idiopathic pulmonary fibrosis but actually worsened it, the ARTEMIS-IPF clinical trial showed.
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news